RUNX2 stabilization by long non-coding RNAs contributes to hypertrophic changes in human chondrocytes

Area of Science:

• Molecular Biology
• Cell Biology
• Biochemistry

Background:

• Chondrocyte hypertrophy is a key process in endochondral ossification and osteoarthritis (OA) pathogenesis.
• Hypertrophic chondrocytes in OA contribute to cartilage destruction and calcification.
• Current therapeutic strategies for OA focus on inflammation and cartilage regeneration, but lack methods to prevent chondrocyte hypertrophy.

Purpose of the Study:

• To identify and characterize novel long non-coding RNAs (lncRNAs) involved in chondrocyte hypertrophy.
• To elucidate the regulatory mechanism of these lncRNAs in chondrocyte hypertrophic differentiation.
• To explore the potential of these lncRNAs as therapeutic targets for osteoarthritis.

Main Methods:

• RNA sequencing to identify lncRNAs (LINC02035, LOC100130207) in hypertrophically differentiating human chondrocytes (TC28a2 cells).
• In vitro assays including western blotting, qPCR, RNA-IP, and in situ hybridization to study lncRNA-RUNX2 interactions.
• Chondrogenic differentiation of mesenchymal stem cells and OA patient-derived chondrocytes were used to validate findings.

Main Results:

• LINC02035 and LOC100130207 were identified as key regulators of chondrocyte hypertrophy.
• These lncRNAs interact with RUNX2, a master regulator of hypertrophy, affecting its protein stability and degradation.
• Knockdown of these lncRNAs prevented hypertrophic changes and protected cartilage matrix proteins (COL2A1, ACAN) from degradation.

Conclusions:

• LINC02035 and LOC100130207 regulate chondrocyte hypertrophy by modulating RUNX2 protein levels.
• These novel lncRNAs represent potential therapeutic targets for preventing or delaying osteoarthritis development.
• Targeting these lncRNAs could be a promising strategy to inhibit chondrocyte hypertrophy in OA.